my008211a
Small moleculeexperimental
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started May 27, 2022 (NCT05642585)
Timeline
Indications
Mechanism of action
- Complement factor BINHIBITOR
CFB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06687174 | Phase 2 | Dec 31, 2024 | Peking University, Wuhan Createrna Science and Technology Co., Ltd |
| NCT06134414 | Phase 2 | Dec 31, 2024 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT06933914 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT06932471 | Phase 3 | Aug 30, 2024 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT06932744 | Phase 3 | Aug 30, 2024 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT06543459 | Phase 1 | Aug 10, 2024 | Fudan University, Wuhan Createrna Science and Technology Co., Ltd |
| NCT06050226 | Phase 2 | Jul 6, 2023 | Chinese Academy of Medical Sciences, Wuhan Createrna Science and Technology Co., Ltd |
| NCT05828472 | Phase 1 | Jan 10, 2023 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT05828485 | Phase 1 | Sep 26, 2022 | Wuhan Createrna Science and Technology Co., Ltd |
| NCT05642585 | Phase 1 | May 27, 2022 | Wuhan Createrna Science and Technology Co., Ltd |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wuhan Createrna Science and Technology Co., Ltd | For profit | 10 | 10 | 3 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1